{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:24:08Z","timestamp":1792347848373,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s12640-012-9316-9","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T09:59:46Z","timestamp":1331287186000},"page":"150-157","source":"Crossref","is-referenced-by-count":31,"title":["The Effect of Adenosine A2A Receptor Antagonists on Hydroxyl Radical, Dopamine, and Glutamate in the Striatum of Rats with Altered Function of VMAT2"],"prefix":"10.1007","volume":"22","author":[{"given":"Krystyna","family":"Go\u0142embiowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dziubina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,10]]},"reference":[{"key":"9316_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03033137","volume":"5","author":"M Asanuma","year":"2003","unstructured":"Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinine formation and tyrosinase in a model of Parkinson\u2019s disease. Neurotox Res 5:165\u2013176","journal-title":"Neurotox Res"},{"key":"9316_CR2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.1052","volume":"50","author":"A Ascherio","year":"2001","unstructured":"Ascherio A, Zhang SH, Hern\u00e1n MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson\u2019s disease in men and women. Ann Neurol 50:56\u201363","journal-title":"Ann Neurol"},{"key":"9316_CR3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","volume":"180","author":"A Carlsson","year":"1957","unstructured":"Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonist. Nature 180:1200","journal-title":"Nature"},{"issue":"6","key":"9316_CR4","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1212\/01.WNL.0000095215.97585.59","volume":"61","author":"N Castagnoli Jr","year":"2003","unstructured":"Castagnoli N Jr, Petzer JP, Steyn S, Castagnoli K, Chen J-F, Schwarzchild MA, Van der Schyf C (2003) Monoamine oxidase B inhibition and neuroprotection. Studies on selective adenosine A2A receptor antagonists. Neurology 61(6):S62\u2013S68","journal-title":"Neurology"},{"key":"9316_CR5","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1523\/JNEUROSCI.0319-07.2007","volume":"27","author":"WM Caudle","year":"2007","unstructured":"Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebroke RE, Di Monte DA, Emson PC, Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27:8138\u20138148","journal-title":"J Neurosci"},{"key":"9316_CR6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pneurobio.2007.09.002","volume":"83","author":"J-F Chen","year":"2007","unstructured":"Chen J-F, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendon\u00e7a A (2007) Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and \u201cfine tuning\u201d modulation. Prog Neurobiol 83:310\u2013331","journal-title":"Prog Neurobiol"},{"key":"9316_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1471-4159.2007.05108.x","volume":"105","author":"M-K Chen","year":"2008","unstructured":"Chen M-K, Kuwabara H, Zhou Y, Adams RJ, Bra\u0161i\u0107 JR, McGloyhan JL, Verina T, Burton NC, Alexander M, Kumar A, Wong DF, Guilarte TR (2008) VMAT2 and dopamine neuron loss in a primate model of Parkinson\u2019s disease. J Neurochem 105:78\u201390","journal-title":"J Neurochem"},{"key":"9316_CR8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/syn.890130410","volume":"13","author":"BA Donzanti","year":"1993","unstructured":"Donzanti BA, Hite JF, Yamamoto BK (1993) Extracellular glutamate levels increase with age in the lateral striatum: potential involvement of presynaptic D-2 receptors. Synapse 13:376\u2013382","journal-title":"Synapse"},{"key":"9316_CR9","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1523\/JNEUROSCI.13-12-05402.1993","volume":"13","author":"S Ferr\u00e9","year":"1993","unstructured":"Ferr\u00e9 S, O\u2019Connor WT, Fuxe K, Ungerstedt U (1993) The striopallidal neuron: a main locus for adenosine\u2013dopamine interactions in the brain. J Neurosci 13:5402\u20135406","journal-title":"J Neurosci"},{"key":"9316_CR10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12640-011-9263-x","volume":"21","author":"K Go\u0142embiowska","year":"2012","unstructured":"Go\u0142embiowska K, Dziubina A (2012) Effect of adenosine A2A receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats. Neurotox Res 21:222\u2013230","journal-title":"Neurotox Res"},{"key":"9316_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12640-009-9016-2","volume":"15","author":"K Go\u0142embiowska","year":"2009","unstructured":"Go\u0142embiowska K, Dziubina A, Kowalska M, Kami\u0144ska K (2009) Effect of adenosine A2A receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum. Neurotox Res 15:155\u2013166","journal-title":"Neurotox Res"},{"key":"9316_CR12","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1471-4159.2006.03907.x","volume":"97","author":"B Halliwell","year":"2006","unstructured":"Halliwell B (2006) Oxidative stress and neurodegeneration: where we are now? J Neurochem 97:1634\u20131658","journal-title":"J Neurochem"},{"key":"9316_CR13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.parkreldis.2008.12.006","volume":"15","author":"P Jenner","year":"2009","unstructured":"Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF (2009) Adenosine, adenosine A2A antagonists, and Parkinson\u2019s disease. Parkinsonism Rel Dis 15:406\u2013413","journal-title":"Parkinsonism Rel Dis"},{"key":"9316_CR14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0006-8993(01)03147-X","volume":"926","author":"N Jonkers","year":"2002","unstructured":"Jonkers N, Sarre S, Ebinger G, Michotte Y (2002) MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res 926:149\u2013155","journal-title":"Brain Res"},{"key":"9316_CR28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1021\/ac00125a006","volume":"58","author":"R Knecht","year":"1986","unstructured":"Knecht R, Chang JY (1986) Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino)azobenzenesulfonyl chloride. Anal Chem 58:2375\u20132379","journal-title":"Anal Chem"},{"key":"9316_CR15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/exnr.2000.7467","volume":"165","author":"CK Meshul","year":"2000","unstructured":"Meshul CK, Cogen JP, Cheng H-W, Moore C, Krentz L, McNeill TH (2000) Alterations in rat striatal glutamate synapses following a lesion of the cortico- and\/or nigrostriatal pathway. Exp Neurol 165:191\u2013206","journal-title":"Exp Neurol"},{"key":"9316_CR16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ana.410410417","volume":"41","author":"GW Miller","year":"1997","unstructured":"Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey Al (1997) Immunochemical analysis of dopamine transporter protein in Parkinson\u2019s disease. Ann Neurol 41:530\u2013539","journal-title":"Ann Neurol"},{"key":"9316_CR17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1006\/exnr.1998.7008","volume":"156","author":"GW Miller","year":"1999","unstructured":"Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson\u2019s disease. Exp Neurol 156:138\u2013148","journal-title":"Exp Neurol"},{"key":"9316_CR18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-0186(98)00052-7","volume":"33","author":"M Morari","year":"1998","unstructured":"Morari M, Marti M, Sbrenna K, Fuxe K, Bianchi C, Beani L (1998) Reciprocal dopamine\u2013glutamate modulation of release in the basal ganglia. Neurochem Int 33:383\u2013397","journal-title":"Neurochem Int"},{"key":"9316_CR19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pneurobio.2007.07.001","volume":"83","author":"M Morelli","year":"2007","unstructured":"Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzchild MA (2007) Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. Prog Neurobiol 83:293\u2013309","journal-title":"Prog Neurobiol"},{"key":"9316_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4522(00)00250-5","volume":"100","author":"M Ochi","year":"2000","unstructured":"Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y (2000) Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100:53\u201362","journal-title":"Neuroscience"},{"key":"9316_CR21","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"1998","unstructured":"Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, San Diego"},{"key":"9316_CR22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0306-4522(95)00168-I","volume":"68","author":"AE Pollack","year":"1995","unstructured":"Pollack AE, Fink JS (1995) Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68:721\u2013728","journal-title":"Neuroscience"},{"key":"9316_CR23","first-page":"35","volume":"4","author":"P Popoli","year":"2004","unstructured":"Popoli P, Blum D, Pintor A, Tebano MT, Frank C, Gianfriddo M, Domenici MR, Schiffmann SN, Pedata F (2004) The controversial role of adenosine receptor antagonists as neuroprotective agents. Curr Med Chem CNS Agents 4:35\u201345","journal-title":"Curr Med Chem CNS Agents"},{"key":"9316_CR24","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","volume":"283","author":"GW Ross","year":"2000","unstructured":"Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung K-H, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674\u20132679","journal-title":"JAMA"},{"key":"9316_CR25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","volume":"29","author":"MA Schwarzschild","year":"2006","unstructured":"Schwarzschild MA, Agnati L, Fuxe K, Chen J-F, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson\u2019s disease. Trends Neurosci 29:647\u2013654","journal-title":"Trends Neurosci"},{"key":"9316_CR26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.neuropharm.2007.08.006","volume":"53","author":"A Tozzi","year":"2007","unstructured":"Tozzi A, Tscherter A, Belcastro V, Tantucci M, Costa C, Picconi B, Centonze D, Calabresi P, Borsini F (2007) Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 53:783\u2013789","journal-title":"Neuropharmacology"},{"key":"9316_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","volume":"105","author":"K Xu","year":"2005","unstructured":"Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A2A receptor antagonists in Parkinson\u2019s disease. Pharmacol Ther 105:267\u2013310","journal-title":"Pharmacol Ther"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12640-012-9316-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T23:56:53Z","timestamp":1561420613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-012-9316-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,10]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["9316"],"URL":"https:\/\/doi.org\/10.1007\/s12640-012-9316-9","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,10]]}}}